Despite this higher risk, there was no evidence of effect modification for the benefits of apixaban over warfarin with regard to stroke/systemic embolism, major bleeding, and allcause mortality. 4, 5 However, subgroup analyses including patients with prior valve repair or replacement were not performed. We aimed to evaluate the safety and efficacy of apixaban vs warfarin in the subgroup of patients from ARISTOTLE with a history of BPV replacement or native valve repair.
| METHODS

ARISTOTLE (NCT00412984) included patients with AF or atrial flutter
and ≥1 risk factors for stroke: age ≥75 years, previous stroke/transient ischemic attack, symptomatic heart failure, diabetes, or hypertension. 4 Patients were randomized to receive apixaban 5 mg twice daily or dose-adjusted warfarin, with a target international normalized ratio of 2.0 to 3.0. A reduced dose of apixaban (2.5 mg twice daily) was given to patients who met ≥2 of the following criteria: age ≥ 80 years, body weight ≤60 kg, serum creatinine ≥1.5 mg/dL. Patients with a history of BPV replacement or native valve repair (valvuloplasty, annuloplasty, commissurotomy) were eligible for inclusion. Those with moderate or severe mitral stenosis or mechanical heart valves were excluded. All patients provided written informed consent, and approval was received from appropriate ethics committees at participating sites. surgery for whom confirmatory data were unable to be obtained from a study site, the surgery was assumed to be BPV replacement (n = 57) 
| RESULTS
Of 18 201 patients enrolled in ARISTOTLE, 251 patients had a history of valve surgery. A total of 95 patients were excluded because lack of study site confirmation of non-aortic valve surgery (n = 90), presence of mechanical valve (n = 4), or right-sided valve repair only (n = 1).
Confirmatory data were unable to be obtained from a study site in 57 patients, thus, valve surgery was assumed to be BPV replacement as described above. Table 1 . Median age was 74 years and 39.1% were female. No significant differences were observed between groups for any of the baseline characteristics analyzed. More patients in the apixaban group had prior stroke, transient ischemic attack, or systemic embolism than those in the warfarin group (27.6% vs 17.4%), but that difference was not significant. Overall clinical event rates were low (Table 2) , with no significant differences between apixaban and warfarin for any outcomes. 
